Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 8, Number 12 December 2009

Review

Bim-targeted cancer therapy: A link between drug action and underlying molecular changes 3173
Toru Akiyama, Crispin R. Dass, and Peter F.M. Choong

Research Articles

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity *in vivo* 3181
Sean G. Buchanan, Jorg Hendle, Patrick S. Lee, Christopher R. Smith, Pierre-Yves Bounaud, Katti A. Jessen, Crystal M. Tang, Nanni H. Huser, Jeremy D. Felce, Karen J. Froning, Marshall C. Peterman, Brandon E. Aubol, Steve F. Gessert, J. Michael Sauder, Kenneth D. Schwinn, Marijane Russell, Isabelle A. Rooney, Jason Adams, Barbara C. Leon, Tuan H. Do, Jeff M. Blaney, Paul A. Sprengeler, Devon A. Thompson, Lydia Smyth, Laura A. Pelletier, Shane Atwell, Kevin Holme, Stephen R. Wasserman, Spencer Emtage, Stephen K. Burley, and Siegfried H. Reich

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells 3191
Feng Sun, Eli Chan, Zhenlong Wu, Xiaojing Yang, Victor E. Marquez, and Qiang Yu

G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells 3203
Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, and Xiao-Feng Zhu

Basal c-Jun NH_2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells 3214
Jian Cui, Qingyang Wang, Jing Wang, Ming Lv, Ning Zhu, Yan Li, Jiannan Feng, Beifen Shen, and Jiyan Zhang

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4 3223
Wen-Bin Tsai, Isamu Aiba, Soo-yong Lee, Lynn Feun, Niramol Savaraj, and Macus Tien Kuo

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models 3234
Mark J. Williamson, Matthew D. Silva, Jennifer Terkelsen, Robbie Robertson, Li Yu, Cindy Xia, Panos Hatsis, Bret Bannerman, Trisha Babcock, Yueying Cao, and Erik Kupperman

A novel two-step transcriptional activation system for gene therapy directed toward epithelial cells 3244
Maja L. Arendt, Lubna Nasir, and Iain M. Morgan

contents continued

Angiotensin type 2 receptor–mediated apoptosis of human prostate cancer cells 3255
Hongwei Li, Yanfei Qi, Chengyao Li, Leah N. Braseth, Yongxin Gao, Arseniy E. Shabashvili, Michael J. Katovich, and Colin Sumners

***In vivo* activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts 3266**
Kaye J. Williams, Mark R. Albertella, Brian Fitzpatrick, Paul M. Loadman, Steven D. Shnyder, Edwin C. Chinje, Brian A. Telfer, Chris R. Dunk, Peter A. Harris, and Ian J. Stratford

Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O^6-methylguanine-DNA methyltransferase 3276
Yuanyuan Gao, Abbas Fotovati, Cathy Lee, Michelle Wang, Gilbert Cote, Emma Guns, Brian Toyota, Damien Faury, Nada Jabado, and Sandra E. Dunn

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative *in vivo* effects against glioblastoma multiforme cells 3285
Jay F. Dorsey, Akiva Mintz, Xiaobing Tian, Melissa L. Dowling, John P. Plastaras, David T. Dicker, Gary D. Kao, and Wafik S. El-Deiry

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer 3296
Rudi Bao, Cheng-Jung Lai, Da-Gong Wang, Hui Qu, Ling Yin, Brian Zifcak, Xu Tao, Jing Wang, Ruzanna Atoyan, Maria Samson, Jeffrey Forrester, Guang-Xin Xu, Steven DellaRocca, Mylissa Borek, Hai-Xiao Zhai, Xiong Cai, and Changgeng Qian

Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D 3307
Caroline Ballot, Jérome Kluza, Alain Martoriati, Ulrika Nyman, Pierre Formstecher, Bertrand Joseph, Christian Bailly, and Philippe Marchetti

Natural product derivative Bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of β-tubulin at Cys 12 and suppression of microtubule dynamics 3318
Wanhong Xu, Biao Xi, Jieying Wu, Haoyun An, Jenny Zhu, Yama Abassi, Stuart C. Feinstein, Michelle Gaylord, Baoqin Geng, Huifang Yan, Weimin Fan, Meihua Sui, Xiaobo Wang, and Xiao Xu

Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G 3331
Heather N. Tinsley, Bernard D. Gary, Adam B. Keeton, Wei Zhang, Ashraf H. Abadi, Robert C. Reynolds, and Gary A. Piazza

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR 3341
Joan M. Carboni, Mark Wittman, Zheng Yang, Francis Lee, Ann Greer, Warren Hurlburt, Stephen Hillerman, Carolyn Cao, Glenn H. Cantor, Janet Dell-John, Cliff Chen, Lorell Discenza, Krista Menard, Aixin Li, George Trainor, Dolatrai Vyas, Robert Kramer, Ricardo M. Attar, and Marco M. Gottardis

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate *in vivo* 3350
Maria L.H. Vlaming, Anita van Esch, Zeliha Pala, Els Wagenaar, Koen van de Wetering, Olaf van Tellingen, and Alfred H. Schinkel

Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth–inhibitory activity 3360
Valentina Appierto, Paola Tiberio, Elena Cavadini, Patrizia Casalini, Graziella Cappelletti, and Franca Formelli

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H: quinone oxidoreductase 1 activity *in vivo* 3369
Mark Douglas, Alice R. Lim, James R. Porter, Kip West, Melissa M. Pink, Jie Ge, Andrew A. Wylie, Thomas T. Tibbits, Kurtis Biggs, Michael Curtis, Vito J. Palombella, Julian Adams, Christian C. Fritz, and Emmanuel Normant

Acknowledgment to Reviewers/Volume 8 3379

Correction

Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts 3388



On the Cover

Nuclear localization of total YB-1 is a classic index of poor prognosis in many types of cancer. The nuclear localization of YB-1 is governed by phosphorylation at S102 leading to enhanced binding to genes associated with tumor growth and drug resistance. The image shows for the first time that glioblastoma multiforme cells express intense levels of activated YB-1 in the nucleus. For details, see article by Gao and colleagues on page 3276.

Note: Supplement to *Molecular Cancer Therapeutics*, Volume 8, Issue 12 (December 2009)
The abstracts of the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 15–19, 2009) are being published as an online-only supplement to the December issue of *Molecular Cancer Therapeutics*. The supplement is available at http://mct.aacrjournals.org/.

Molecular Cancer Therapeutics is abstracted or indexed in MEDLINE/Index Medicus, Chemical Abstracts (STN), Biological Abstracts, Biochemistry & Biophysics Citation Index, BIOSYS Previews® Database, and Science Citation Index. *Molecular Cancer Therapeutics* is also published online. Please visit http://mct.aacrjournals.org.

Authors...Submit your papers **online** at
mct.msubmit.net